Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis

J Med Virol. 2023 Feb;95(2):e28471. doi: 10.1002/jmv.28471.

Authors

Huzaifa A Cheema¹, Uzair Jafar¹, Aruba Sohail², Abia Shahid¹, Syeda Sahra³, Muhammad Ehsan¹, Farwa Athar¹, Jaffer Shah⁴, Ranjit Sah⁵

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
² Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
³ Department of Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
⁴ New York State Department of Health, Albany, New York, USA.
⁵ Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.

PMID: 36606609
DOI: 10.1002/jmv.28471

No abstract available

Publication types

Meta-Analysis
Systematic Review
Letter

MeSH terms

COVID-19 Drug Treatment
COVID-19*
Classification
Humans
Ritonavir*

Substances

nirmatrelvir
Ritonavir